Challenges in Rare Diseases Treatment

There are approximately 7,000 rare diseases, which from a regulatory perspective are defined as those diseases where there are less than 200,000 patients in the US or that affect no more than five in 10,000 of the general population in the EU. "Orphan drugs" are medicinal products intended for diagnosis, prevention or treatment of life-threatening or debilitating rare diseases. They are "orphans" because the pharmaceutical industry has little interest under normal market conditions in developing and marketing drugs intended for only a small number of patients suffering from very rare conditions.

  • Different types of rare diseases
  • Misperceptions about rare diseases
  • Role of Patient Registries
  • Regulatory Approaches and Alternative Methodologies
  • Rising Patient Costs
  • Reimbursement Strategies

Related Conference of Challenges in Rare Diseases Treatment

August 21-23, 2017

3rd Annual Congress on Infectious Diseases

San Francisco, California, USA
September 04-05, 2017

Global Experts Meeting on Sexually Transmitted Diseases

Macau, Hong Kong
September 7-9, 2017

6thEuro-Global Conference on Infectious Diseases

Paris, France
September 13-14, 2017

6th Annual Bacteriology and Parasitology Meeting

Singapore
October 30-November 1, 2017

3rd Annual Congress on Rare Diseases and Orphan Drugs


(10 Plenary Forums - 1 Event)
San Antonio, Texas, USA
March 1-2, 2018

5th International congress on Infectious Diseases

Berlin, Germany

Challenges in Rare Diseases Treatment Conference Speakers

Recommended Sessions

Related Journals

Are you interested in